Actively Recruiting

Phase 2
Age: 18Years - 75Years
FEMALE
NCT06654440

A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2024-12-10

100

Participants Needed

1

Research Sites

102 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.

CONDITIONS

Official Title

A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

Who Can Participate

Age: 18Years - 75Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Participate voluntarily and sign informed consent
  • Have recurrent or metastatic gynecological cancer that failed standard treatments
  • Have at least one measurable tumor lesion (RECIST version 1.1)
  • Have an ECOG performance status of 0 to 1
  • Have adequate organ function
  • Female of childbearing potential must agree to use highly effective contraception during treatment and for 7 months after last dose
  • Female participants must have a negative HCG test within 72 hours before enrollment and must not be breastfeeding
Not Eligible

You will not qualify if you...

  • Have untreated brain metastasis, meningeal metastasis, or spinal cord compression
  • Have other previous or current cancers unless in complete remission for at least 5 years and not requiring treatment
  • Previously received antibody drug conjugates with topoisomerase I inhibitors
  • Had major surgery (other than biopsy) within 28 days prior to first dose or minor traumatic surgery within 7 days prior
  • Are HIV positive, have active hepatitis B or C
  • Had active pulmonary tuberculosis within 1 year prior to enrollment
  • Are allergic to any components of SHR-A2102
  • Are judged unfit to participate by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China, 510060

Actively Recruiting

Loading map...

Research Team

Z

ZhiFei Lin, M.M

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here